James Patrick Allison

James Patrick Allison, Ph.D., is Regental Professor and Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center, where he holds the Olga Keith Wiess Distinguished University Chair for Cancer Research and the Vivian Smith Distinguished Chair in Immunology. He serves as Director of the Parker Institute for Cancer Immunotherapy at MD Anderson and Director of the James P. Allison Institute, established in 2022. Dr. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine, shared with Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." In the early 1990s at the University of California, Berkeley, Allison studied the T-cell protein CTLA-4 and discovered that it functions as an inhibitory molecule to restrict T-cell responses. His landmark 1996 Science publication demonstrated that antibody blockade of CTLA-4 could enhance anti-tumor immune responses and eliminate established tumors in mice—the first proof that "releasing the brakes" on the immune system could effectively combat cancer. This revolutionary finding challenged conventional wisdom that focused on activating immunity. Allison's work directly led to the development of ipilimumab (Yervoy), approved by the FDA in 2011 for metastatic melanoma—the first FDA-approved immune checkpoint inhibitor. His subsequent research demonstrated synergistic effects of combined PD-1 and CTLA-4 blockade, establishing the scientific foundation for combination immunotherapy regimens now approved for multiple cancer types. Allison has received numerous prestigious honors including the 2015 Lasker-DeBakey Clinical Medical Research Award, the inaugural 2014 Tang Prize in Biopharmaceutical Science, the 2014 Breakthrough Prize in Life Sciences ($3 million), and the Canada Gairdner International Award. After joining MD Anderson in 2012 from Berkeley (where he directed the Cancer Research Laboratory from 1985-2004), he built the Immunotherapy Platform and trained the next generation of cancer immunologists. As Director of the Parker Institute for Cancer Immunotherapy, Allison leads multi-institutional collaborations developing next-generation immunotherapies. His career exemplifies the complete translational pathway from fundamental discovery to clinical impact, transforming cancer treatment paradigms and benefiting millions of patients worldwide.

James Patrick Allison博士是德克萨斯大学MD Anderson癌症中心免疫学系主任和Regental教授,持有Olga Keith Wiess癌症研究杰出大学教席和Vivian Smith免疫学杰出教席。他担任MD Anderson癌症免疫治疗Parker研究所主任和2022年成立的James P. Allison研究所主任。 Allison博士因"发现负性免疫调节在癌症治疗中的应用"与本庶佑共同获得2018年诺贝尔生理学或医学奖。1990年代初在加州大学伯克利分校,Allison研究T细胞蛋白CTLA-4,发现其作为抑制分子限制T细胞反应。他1996年在Science发表的里程碑论文证明CTLA-4抗体阻断可增强抗肿瘤免疫反应并消除小鼠已建立的肿瘤——首次证明"释放免疫系统刹车"可有效对抗癌症。 这一革命性发现挑战了专注于激活免疫的传统观念。Allison的工作直接促成ipilimumab (Yervoy)的开发,该药2011年获FDA批准治疗转移性黑色素瘤,成为首个FDA批准的免疫检查点抑制剂。他后续研究证明PD-1与CTLA-4联合阻断的协同效应,为现已批准用于多种癌症类型的组合免疫治疗方案奠定科学基础。 Allison获得众多顶级荣誉,包括2015年Lasker-DeBakey临床医学研究奖、2014年首届Tang Prize生物医药科学奖、2014年生命科学突破奖(300万美元)和加拿大Gairdner国际奖。2012年从伯克利加入MD Anderson后(1985-2004年在伯克利担任癌症研究实验室主任),他建立了免疫治疗平台并培养了新一代癌症免疫学家。作为Parker癌症免疫治疗研究所主任,Allison领导多机构合作开发下一代免疫疗法。他的职业生涯体现了从基础发现到临床影响的完整转化路径,改变了癌症治疗范式,使全球数百万患者受益。